Table 3. In vitro binding potential and Aβ40/42 protein levels.
| study group | soluble protein | insoluble protein | binding potential | ||
| Aβx–40 | Aβx–42 | Aβx–40 | Aβx–42 | ||
| huCTL | 0.7 | 1 | 15.9 | 23.1 | 0 |
| huAD-0 | 0.8 | 1.6 | 15.8 | 121.9 | 0 |
| huAD-C | 5.8 | 28.5 | 120.5 | 449.9 | 38.2 |
| tg-old | 517.8 | 186.2 | 169915.9 | 145010.5 | 11.9 |
| tgtg-young | 450.5 | 304.8 | 172152.3 | 178821.1 | 14.3 |
| tgtg-old | 912.4 | 485.4 | 657818.2 | 572182.5 | 69.2 |
In vitro binding potential (BP) as yielded with [3H]PiB radioligand saturation binding assay and corresponding soluble and insoluble Aβx–40 and Aβx–42 protein fractions (picogram protein per milligram wet tissue) for the same human and mouse tissue samples. Binding curves of the severe human AD and all transgenic mouse brain samples are shown in Figure 5.